A medical technology company at the forefront of predictive diagnostics and precision medicine.
The Company specialises in proteomics - the industrial scale study of the structure and function of proteins.
Our mission is to improve the quality of lives by the creation and application of innovative tools that enable the proactive treatment of disease.
Proteomics International has developed PromarkerD, a prognostic test for diabetic kidney disease, a progressive disorder found in 1-in-3 adults with diabetes.
The prevalence of kidney disease is rising rapidly, and many patients progress to need renal dialysis or a kidney transplant.
In peer reviewed clinical studies PromarkerD correctly predicted 86% of otherwise healthy people with diabetes who went on to develop chronic kidney disease within four years.